Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Podcast Summary

Introduction

Dr. Warrick is a practicing cardiologist and author dedicated to educating patients about heart health and the latest advances in cardiac care. In this episode, he discusses four recent cardiovascular breakthroughs: aged black garlic's blood pressure effects, smart wearable devices for detecting atrial fibrillation and sleep apnea, renal artery denervation for treatment-resistant hypertension, and a new RNA-based therapy for lowering lipoprotein(a).

Key Takeaways:

• Aged black garlic (ABG) containing S-allylcysteine (SAC) demonstrated the ability to reduce diastolic blood pressure by approximately 6 mmHg in a Spanish clinical trial of 67 healthy men.

• A 5-6 mmHg reduction in diastolic blood pressure correlates to roughly 40% reduction in stroke risk and 30% reduction in heart attack risk, making aged black garlic's effects potentially very significant.

• Wearable smart devices using photoplethysmography (PPG) technology can effectively detect atrial fibrillation, identifying 0.4% prevalence in a low-risk population over four years with 93% detection accuracy.

• Advanced algorithms in smartwatches can now assess multiple cardiovascular and respiratory parameters including obstructive sleep apnea, with detection of OSA in approximately 18,000 out of 900,000 tested users.

• The SPIRAL hypertension trial demonstrated that renal artery denervation (ablating sympathetic nerves in renal arteries) maintains its blood pressure-lowering effects of 10 mmHg systolic and 5 mmHg diastolic reduction at three years post-intervention.

• The SPIRAL trial used a sham procedure as a placebo control, ensuring results exceeded pure placebo effects and validating the true effectiveness of the intervention.

• The Apollo trial revealed that a small interfering RNA (siRNA) therapy achieved nearly 98% lowering of lipoprotein(a), a dangerous LDL-like particle associated with premature coronary artery disease and aortic stenosis.

• The siRNA therapy additionally provided a 25% reduction in LDL cholesterol, offering dual cardiovascular benefits in treating this emerging high-risk cholesterol particle.